Akums Drugs & Pharma Intrinsic Value
Akums Drugs & Pharma (AKUMS) median intrinsic value is ₹554.84 from 9 valuation models (range ₹160–₹1333), vs current price ₹533.20 — +4.1% upside (Trading Near Calculated Value), margin of safety 3.9%. For current market price and key ratios, visit Akums Drugs & Pharma share price today.
AKUMS Valuation Methods Summary — DCF, Graham Number & P/E
Akums Drugs & Pharma intrinsic value across 9 models vs current price ₹533.20 — upside/downside and value range per method. Browse AKUMS cash flow statement for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹234.08 | ₹187.26 - ₹280.90 | -56.1% | EPS: ₹10.64, Sector P/E: 22x |
| Book Value Method | asset | ₹1333.00 | ₹1199.70 - ₹1466.30 | +150.0% | Book Value/Share: ₹988.39, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1066.40 | ₹959.76 - ₹1173.04 | +100.0% | Revenue/Share: ₹1354.84, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1066.40 | ₹959.76 - ₹1173.04 | +100.0% | EBITDA: ₹508.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹1333.00 | ₹1066.40 - ₹1599.60 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹159.96 | ₹143.96 - ₹175.96 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹164.39 | ₹147.95 - ₹180.83 | -69.2% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹554.84 | ₹499.36 - ₹610.32 | +4.1% | ROE: 5.6%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹486.44 | ₹437.80 - ₹535.08 | -8.8% | EPS: ₹10.64, BVPS: ₹988.39 |
AKUMS Intrinsic Value vs Market Price — All Valuation Models
Akums Drugs & Pharma fair value range ₹160–₹1333 vs current market price ₹533.20 across 9 valuation models. Compare with AKUMS intrinsic value calculation to assess whether the stock is under or overvalued.
AKUMS Intrinsic Value Analysis — Undervalued or Overvalued?
Akums Drugs & Pharma median intrinsic value ₹554.84, current price ₹533.20 — Trading Near Calculated Value by 4.1%, margin of safety 3.9%.
What is the intrinsic value of AKUMS?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Akums Drugs & Pharma (AKUMS) is ₹554.84 (median value). With the current market price of ₹533.20, this represents a +4.1% variance from our estimated fair value.
The valuation range spans from ₹159.96 to ₹1333.00, indicating ₹159.96 - ₹1333.00.
Is AKUMS undervalued or overvalued?
Based on our multi-method analysis, Akums Drugs & Pharma (AKUMS) appears to be trading near calculated value by approximately 4.1%.
AKUMS Financial Health — Key Ratios vs Industry Benchmarks
Akums Drugs & Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 14.58 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 5.6% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 9.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.02x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
AKUMS Cash Flow Quality — Operating & Free Cash Flow
Akums Drugs & Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹465 Cr | ₹191 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹498 Cr | ₹333 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹177 Cr | ₹25 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹32 Cr | ₹-86 Cr | Positive Operating Cash Flow | 6/10 |
| March 2021 | ₹131 Cr | ₹77 Cr | Positive Free Cash Flow | 8/10 |